Novonesis AS News - NZM2

Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21 Novonesis will host a conference call...

Resolutions from the Extraordinary Shareholders’ Meeting 2024 Company Announcement no. 10 March 4, 2024Today an extraordinary shareholders’...

Invitation to an extraordinary shareholders’ meeting of Novozymes A/S An extraordinary shareholders’ meeting of Novozymes A/S will be held...

The Novozymes Report 2023 This annual report has been released subsequent to the approval of the combination of Novozymes and Chr. Hansen on...

Trading by management and close relations of management Trading by management and close relations of management In accordance with...

Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed Settlement of the combination of Novozymes...

Legacy Novozymes delivers solid last full-year results Legacy Novozymes is delivering solid growth and earnings in a year characterized by...

Results update for 2023 – unaudited 6% organic sales growth in Q4 and 5% for the full year with solid margins and free cash flow generation...

Total number of voting rights and capital on January 31, 2024 Total number of voting rights and capital on January 31, 2024 January...

Trading by management and close relations of management January 29, 2024Company announcement No. 04 Trading by management and...

Major shareholder announcement Major shareholder announcement January 29, 2024Company announcement No. 03 On January...

The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partner Today...